"Neuroendocrine Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Descriptor ID |
D018358
|
| MeSH Number(s) |
C04.557.465.625.650 C04.557.580.625.650
|
| Concept/Terms |
Neuroendocrine Tumors- Neuroendocrine Tumors
- Neuroendocrine Tumor
- Tumor, Neuroendocrine
- Tumors, Neuroendocrine
|
Below are MeSH descriptors whose meaning is more general than "Neuroendocrine Tumors".
Below are MeSH descriptors whose meaning is more specific than "Neuroendocrine Tumors".
This graph shows the total number of publications written about "Neuroendocrine Tumors" by people in this website by year, and whether "Neuroendocrine Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2004 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 0 | 2 |
| 2013 | 3 | 0 | 3 |
| 2014 | 6 | 0 | 6 |
| 2015 | 5 | 1 | 6 |
| 2016 | 2 | 2 | 4 |
| 2017 | 4 | 0 | 4 |
| 2018 | 4 | 0 | 4 |
| 2019 | 7 | 0 | 7 |
| 2020 | 4 | 0 | 4 |
| 2021 | 3 | 0 | 3 |
| 2022 | 6 | 0 | 6 |
| 2023 | 8 | 0 | 8 |
| 2024 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuroendocrine Tumors" by people in Profiles.
-
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
-
Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients. Radiol Oncol. 2024 Sep 01; 58(3):348-356.
-
[Imaging of pancreatic neuroendocrine tumors]. Radiologie (Heidelb). 2024 Jul; 64(7):559-567.
-
Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors. Radiol Oncol. 2024 06 01; 58(2):196-205.
-
Diagnostics and Imaging for Pancreatic Neuroendocrine Tumors. Surg Clin North Am. 2024 Aug; 104(4):883-890.
-
Primary Tumor Resection and Its Implications in the Modern Treatment Era of Metastatic Small Bowel Neuroendocrine Tumors : Editorial on: "Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors". Ann Surg Oncol. 2024 Apr; 31(4):2187-2189.
-
Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM. Radiol Oncol. 2023 12 01; 57(4):436-445.
-
Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases. Am J Surg. 2024 Mar; 229:17-23.
-
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2023 11 01; 30(11).
-
Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT. Diagn Interv Imaging. 2024 Jan; 105(1):15-25.